Dichloroacetate causes reversible demyelination in vitro: Potential mechanism for its neuropathic effect

Journal of Neurochemistry

Volumn 100, Issue 2, 2007, Pages 429-436

  Felitsyn, Natalia ^a   Stacpoole, Peter W ^a,b   Notterpek, Lucia ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Dorsal root ganglia neurons; Myelin; Myelination; Neurofilament; Peripheral neuropathy; Schwann cells

Indexed keywords

DICHLOROACETIC ACID; INTERMEDIATE FILAMENT PROTEIN; LACTATE DEHYDROGENASE; MYELIN ASSOCIATED GLYCOPROTEIN; MYELIN BASIC PROTEIN; NEUROFILAMENT PROTEIN; NEUROTROPHIN RECEPTOR; PERIPHERAL MYELIN PROTEIN 22; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY LABELING; ARTICLE; CELL CULTURE; CELL ISOLATION; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; DEMYELINATION; DOSE RESPONSE; GLIA CELL; IMMUNOBLOTTING; IN VITRO STUDY; MYELINATION; NERVE CELL; NEUROPATHY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; SCHWANN CELL; SPINAL GANGLION; STEADY STATE;

ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; CELL DEATH; CELLS, CULTURED; COCULTURE TECHNIQUES; DEMYELINATING DISEASES; DICHLOROACETATE; DOSE-RESPONSE RELATIONSHIP, DRUG; GANGLIA, SPINAL; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; MYELIN BASIC PROTEINS; MYELIN P0 PROTEIN; MYELIN PROTEINS; MYELIN-ASSOCIATED GLYCOPROTEIN; NEURONS; RATS; SCHWANN CELLS; SCIATIC NERVE;

EID: 33845802482     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.04248.x     Document Type: Article

References (30)

1. Archelos J. J., Roggenbuck K., Schneider-Schaulies J., Linington C., Toyka K. V. and Hartung H. P. (1993) Production and characterization of monoclonal antibodies to the extracellular domain of P0. J. Neurosci. Res. 35, 46-53.
2. Barshop B. A., Naviaux R. K., McGowan K. A., Levine F., Nyhan W. L., Loupis-Geller A. and Haas R. H. (2004) Chronic treatment of mitochondrial disease patients with dichloroacetate. Mol. Genet. Metab. 83, 138-149.
3. Bhat H. K., Kanz M. F., Campbell G. A. and Ansari G. A. (1991) Ninety-day toxicity study of chloroacetic acids in rats. Fundam. Appl. Toxicol. 17, 240-253.
4. Cicmanec J. L., Condie L. W., Olson G. R. and Wang S. R. (1991) Ninety-day toxicity study of dichloroacetate in dogs. Fundam. Appl. Toxicol. 17, 376-389.
5. Curry S. H., Chu P. I., Baumgartner T. G. and Stacpoole P. W. (1985) Plasma concentrations and metabolic effects of intravenous sodium dichloroacetate. Clin. Pharmacol. Ther 37, 89-93.
6. Curry S. H., Lorenz A., Chu P. I., Limacher M. and Stacpoole P. W. (1991) Disposition and pharmacodynamics of dichloroacetate (DCA) and oxalate following oral DCA doses. Biopharm. Drug Dispos. 12, 375-390.
7. Eichberg J. (2002) Myelin P0: new knowledge and new roles. Neurochem. Res. 27, 1331-1340.
8. Einheber S., Milner T. A., Giancotti F. and Salzer J. L. (1993) Axonal regulation of Schwann cell integrin expression suggests a role for α6 β4 in myelination. J. Cell Biol. 123, 1223-1236.
9. Fotakis G. and Timbrell J. A. (2006) In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol. Lett. 160, 171-177.
10. Fox A. W., Sullivan B. W., Buffini J. D., Neichin M. L., Nicora R., Hoehler F. K., O'Rourke R. and Stoltz R. R. (1996) Reduction of serum lactate by sodium dichloroacetate, and human pharmacokinetic-pharmacodynamic relationships. J. Pharmacol. Exp. Ther. 279, 686-693.
11. Jessen K. R. and Mirsky R. (1999) Schwann cells and their precursors emerge as major regulators of nerve development. Trends Neurosci. 22, 402-410.
12. Katz R., Tai C. N., Diener R. M., McConnell R. F. and Semonick D. E. (1981) Dichloroacetate, sodium: 3-month oral toxicity studies in rats and dogs. Toxicol. Appl. Pharmacol. 57, 273-287.
13. Kaufmann P., Engelstad K., Wei Y. et al. (2006) Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 66, 324-330.
14. Kleitman N., Wood P. M. and Bunge R. P. (1998) Tissue culture methods for the study of myelination, in Culturing Nerve Cells, 2nd edn. (Banker, G. and Goslin, K., eds), pp. 545-594. MIT Press, Cambridge, MA.
15. Kurlemann G., Paetzke I., Moller H., Masur H., Schuierer G., Weglage J. and Koch H. G. (1995) Therapy of complex I deficiency: peripheral neuropathy during dichloroacetate therapy. Eur. J. Pediatr 154, 928-932.
16. Lobner D. (2000) Comparison of the LDH and MTT assays for quantifying cell death: validity for neuronal apoptosis? J. Neurosci. Meth. 96, 147-152.
17. Moore G. W., Swift L. L., Rabinowitz D., Crofford O. B., Oates J. A. and Stacpoole P. W. (1979) Reduction of serum cholesterol in two patients with homozygous familial hypercholesterolemia by dichloroacetate. Atherosclerosis 33, 285-293.
18. Moser V. C., Phillips P. M., McDaniel K. L. and MacPhail R. C. (1999) Behavioral evaluation of the neurotoxicity produced by dichloroacetic acid in rats. Neurotoxicol. Teratol. 21, 719-731.
19. Notterpek L., Snipes G. J. and Shooter E. M. (1999) Temporal expression pattern of peripheral myelin protein 22 during in vivo and in vitro myelination. Glia 25, 358-369.
20. Quarles R. H., Macklin W. B. and Morell P. (2006) Myelin formation, structure and biochemistry, in Basic Neurochemistry (Siegel, G. J., Alberts, R. K., Brady, S. T. and Price, D. L., eds), pp. 51-71. Elsevier. Academic Press, Amsterdam.
21. Sasaki T., Gotow T., Shiozaki M., Sakaue F., Saito T., Julien J. P., Uchiyama Y. and Hisanaga S. (2006) Aggregate formation and phosphorylation of neurofilament-L Pro22 Charcot-Marie-Tooth disease mutants. Hum. Mol. Genet. 15, 943-952.
22. Schachner M., Martini R., Hall H. and Orberger G. (1995) Functions of the L2/HNK-1 carbohydrate in the nervous system. Prog. Brain Res. 105, 183-188.
23. Spruijt L., Naviaux R. K., McGowan K. A., Nyhan W. L., Sheean G., Haas R. H. and Barshop B. A. (2001) Nerve conduction changes in patients with mitochondrial diseases treated with dichloroacetate. Muscle Nerve 24, 916-924.
24. Stacpoole P. W. (1989) The pharmacology of dichloroacetate. Metabolism 38, 1124-1144.
25. Stacpoole P. W., Moore G. W. and Kornhauser D. M. (1979) Toxicity of chronic dichloroacetate. N. Engl. J. Med. 300, 372.
26. Stacpoole P. W., Henderson G. N., Yan Z. M., Cornett R. and James M. O. (1998) Pharmacokinetics, metabolism, and toxicology of dichloroacetate. Drug Metab. Rev. 30, 499-539.
27. Stacpoole P. W., Kerr D. S., Barnes C., Bunch S. T., Carney P. R. et al. (2006a) Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 117, 1519-1531.
28. Stacpoole P. W., Shroads A. L., Felitsyn N. M., Notterpek L. and Calcutt N. A. (2006b) Mechanism of age dependence of dichloroacetate-induced peripheral neuropathy. Mitochondrion 6, 17-18.
29. Weinmaster G. and Lemke G. (1990) Cell-specific cyclic AMP-mediated induction of the PDGF receptor. EMBO J. 9, 915-920.
30. Yount E. A., Felten S. Y., O'Connor B. L., Peterson R. G., Powell R. S., Yum M. N. and Harris R. A. (1982) Comparison of the metabolic and toxic effects of 2-chloropropionate and dichloroacetate. J. Pharmacol. Exp. Ther. 222, 501-508.